{"id":952878,"date":"2026-05-11T15:32:24","date_gmt":"2026-05-11T15:32:24","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/952878\/"},"modified":"2026-05-11T15:32:24","modified_gmt":"2026-05-11T15:32:24","slug":"revolution-medicines-rvmd-receives-fdas-safe-to-proceed-letter-for-daraxonrasib","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/952878\/","title":{"rendered":"Revolution Medicines (RVMD) Receives FDA\u2019s \u201cSafe to Proceed\u201d Letter for Daraxonrasib"},"content":{"rendered":"\n

Revolution Medicines, Inc. (NASDAQ:RVMD<\/a>) is one of the best performing healthcare stocks so far in 2026<\/strong><\/a>. Revolution Medicines, Inc. (NASDAQ:RVMD) announced on May 1 that the U.S. Food and Drug Administration (FDA) issued a \u201csafe to proceed\u201d letter to the company, allowing the initiation of an expanded access treatment protocol (EAP) for daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). Daraxonrasib is an investigational RAS(ON) inhibitor.<\/p>\n

\"Is Is Revolution Medicines, Inc. (RVMD) Among Stocks With At Least $20 Million In Insider Spending Recently? <\/p>\n

The company further stated that the EAP aims to offer treatment access in a monitored and controlled setting, consistent with FDA regulations governing investigational medicines. It added that the authorization marks a crucial step in the process of opening an EAP, and Revolution Medicines, Inc. (NASDAQ:RVMD) is \u201cmoving as quickly as possible\u201d to ensure safe and equitable access to daraxonrasib for eligible patients in the United States. Management also stated that, as per FDA regulations governing expanded access programs, the company is unable to accept direct requests from caregivers or patients, and all requests for expanded access are required to be initiated by a licensed treating physician.<\/p>\n

Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies. It discovers and develops cancer treatments through novel combination and monotherapy treatment regimens that enhance clinical benefits.<\/p>\n

While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/strong><\/a>.<\/p>\n

READ NEXT: <\/strong>15 Stocks That Will Make You Rich in 10 Years<\/strong><\/a> AND <\/strong>12 Best Stocks That Will Always Grow<\/strong><\/a>.<\/strong><\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/strong><\/a>.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best performing healthcare stocks so far in 2026. Revolution Medicines,…\n","protected":false},"author":2,"featured_media":952879,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[199747,61726,25096,105,4326,16,15],"class_list":{"0":"post-952878","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-eap","9":"tag-expanded-access","10":"tag-food-and-drug-administration","11":"tag-health","12":"tag-medication","13":"tag-uk","14":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116556670589630927","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/952878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=952878"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/952878\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/952879"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=952878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=952878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=952878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}